The identification of experimental models that recapitulate human cancers designed to predict patient clinical response to therapies is a major break in oncology. Cancer stem cells (CSCs) represent a small tumor cell population responsible for drug resistance, where their effective killing may lead to identifying better treatment options. While the CSCs hypothesis highlights the need for a specific tumor target, patient-derived xenografts (PDXs) should also be considered for drug development as they better represent tumor heterogeneity and the environment in which a tumor develops.
CITATION STYLE
Porru, M., Pompili, L., Caruso, C., & Leonetti, C. (2018). Xenograft as in vivo experimental model. In Methods in Molecular Biology (Vol. 1692, pp. 97–105). Humana Press Inc. https://doi.org/10.1007/978-1-4939-7401-6_9
Mendeley helps you to discover research relevant for your work.